Evidence map›Paper›PMID 34198999›Full record

ArticlePharmaceutics2021

Radioimmunotheranostic Pair Based on the Anti-HER2 Monoclonal Antibody: Influence of Chelating Agents and Radionuclides on Biological Properties.

Ana Cláudia Camargo Miranda, Sofia Nascimento Dos Santos, Leonardo Lima Fuscaldi, Luiza Mascarenhas Balieiro, Maria Helena Bellini, Maria Inês Calil Cury Guimarães, Elaine Bortoleti de Araújo

Abstract read
In one paragraph

Article in Pharmaceutics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Affibody-based targeting agentFrontiers in medicine · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Ana Cláudia Camargo MirandaHospital Israelita Albert Einstein, Instituto Israelita de Ensino e Pesquisa, Sao Paulo 05652-900, Brazil.ORCID 0000-0002-0232-5138
Sofia Nascimento Dos SantosInstituto de Pesquisas Energéticas e Nucleares, IPEN/CNEN, Sao Paulo 05508-000, Brazil.
Leonardo Lima FuscaldiDepartamento de Ciências Fisiológicas, Faculdade de Ciências Médicas da Santa Casa de São Paulo, Sao Paulo 01221-020, Brazil.ORCID 0000-0001-7864-1324
Luiza Mascarenhas BalieiroInstituto de Pesquisas Energéticas e Nucleares, IPEN/CNEN, Sao Paulo 05508-000, Brazil.
Maria Helena BelliniInstituto de Pesquisas Energéticas e Nucleares, IPEN/CNEN, Sao Paulo 05508-000, Brazil.ORCID 0000-0003-2852-6189
Maria Inês Calil Cury GuimarãesInstituto de Radiologia do Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, Sao Paulo 05403-911, Brazil.
Elaine Bortoleti de AraújoInstituto de Pesquisas Energéticas e Nucleares, IPEN/CNEN, Sao Paulo 05508-000, Brazil.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The oncogene HER2 is an important molecular target in oncology because it is associated with aggressive disease and the worst prognosis. The development of non-invasive imaging techniques and target therapies using monoclonal antibodies is a rapidly developing field. Thus, this work proposes the study of the radioimmunotheranostic pair, [

Indexed as

[111In]In-DTPA-trastuzumab[177Lu]Lu-DOTA-trastuzumabbreast cancerHER2 oncogeneradioimmunoconjugateradioimmunotheranostic pair

Identifiers

PMID34198999
PMCPMC8309196

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.